Nippon Life Global Investors Americas Inc. lifted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 0.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 93,910 shares of the company’s stock after buying an additional 630 shares during the quarter. Eli Lilly and Company makes up 3.7% of Nippon Life Global Investors Americas Inc.’s holdings, making the stock its 6th largest position. Nippon Life Global Investors Americas Inc.’s holdings in Eli Lilly and Company were worth $85,024,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Core Wealth Advisors Inc. grew its position in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares in the last quarter. Lynx Investment Advisory purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $32,000. LGT Financial Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $36,000. Frank Rimerman Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $37,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of Eli Lilly and Company during the first quarter worth $40,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, major shareholder Lilly Endowment Inc sold 58,749 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $915.26, for a total transaction of $53,770,609.74. Following the completion of the transaction, the insider now directly owns 97,308,620 shares of the company’s stock, valued at $89,062,687,541.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders sold 425,000 shares of company stock worth $394,455,351. 0.13% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on Eli Lilly and Company
Eli Lilly and Company Trading Up 0.7 %
Shares of Eli Lilly and Company stock opened at $921.49 on Monday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company has a market capitalization of $875.79 billion, a P/E ratio of 135.71, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53. The company’s fifty day moving average is $895.06 and its two-hundred day moving average is $838.73.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- How to Invest in the FAANG Stocks
- See Why Oracle’s Cloud Infrastructure Growth Demands Attention
- What Does a Stock Split Mean?
- Darden Restaurants Is on the Verge of a Significant Breakout
- Using the MarketBeat Dividend Yield Calculator
- Onsemi Could Be Set Up For a Solid Rebound: Here’s Why
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.